Granules is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $3.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Granules's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Jakafi | Incyte | Generic | 2028 | Settled, terms confidential | $3.1B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Granules's share of it.